# Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

> **NCT04822298** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 3 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- NSCLC

## Interventions

- **DRUG:** AMG 160

## Key facts

- **NCT ID:** NCT04822298
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-31
- **Primary completion:** 2021-12-08
- **Final completion:** 2022-01-26
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Amgen made a business decision to discontinue AMG 160 20180273
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04822298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04822298, "Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04822298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*